Abstract:ObjectiveTo assess the correlation between Z‐scores of positive NIPT results and the positive predictive value (PPV) of non‐invasive prenatal testing (NIPT). MethodsPregnancies with positive NIPT results at Guangzhou Women and Children's Medical Centre between July 2017 and May 2020 were included in this study. Fetal karyotyping or microarray analysis was provided to patients with abnormal NIPT results for confirmatory testing. Logistic regression analyses was applied to study the relationship between the Z scores and the PPV performance. The optimal cut‐off values for indicating fetal common trisomies were obtained based on receiver operating characteristic (ROC) curve analysis, and then the PPV were calculated in pregnancies with positive NIPT results at Z‐score greater than or equal to cut‐off value and in patients with a Z‐score between 3 and cut‐off value respectively. ResultsA total of 214 pregnancies with positive NIPT results for fetal common trisomies were validated by invasive prenatal diagnosis and follow up in this study. Of these, NIPT indicated trisomy 13 in 25 cases, trisomy 18 in 54 cases and trisomy 21 in 135 patients. Logistic regression analyses showed a significant association (P<0.05) between the Z‐scores and true positive results for T21 and T18. For T13, the significant association was not observed (P>0.05). The ROC curve analysis showed that the optimal cut‐off Z‐score for indicating fetal trisomies 13, 18 and 21 were 6.889, 7.574 and 6.612 respectively, and the corresponding area under curve were 0.706, 0.916 and 0.954. In this cohort with abnormal NIPT results, the cut‐off values revealed a sensitivity of 96.8% and a specificity of 90% for indicating trisomies 21, and a sensitivity of 88.9% and a specificity of 92.6% for trisomies 18. However, probably due to the sample size, the sensitivity and specificity for indicating trisomy 13 were lower (85.7% and 61.1%) than that for trisomies 21 and 18. The positive predictive values in pregnancies with positive NIPT results at Z‐score greater than or equal to cut‐off value were 99.18% (121/122) for trisomy 21, 92.31% (24/26) for trisomy 18 and 46.15% (6/13) for trisomy 13. In patients with a Z‐score between 3 and cut‐off Z‐score, the PPV of NIPT for trisomies 21, 18 and 13 were 30.77% (4/13), 10.71% (3/28) and 8.33% (1/12) respectively. Moreover, by classifying Z scores as 3≤Z<5, 5≤Z<10, and Z≥10, the majority of Z scores were above 10 with a PPV of 99% for T21 and just 5.2% were between 3 and 5 with a PPV of 14.3%. In contrast for T18, over a third of tests had Z scores between 3 and 5. The PPV in this group is just over 5%. ConclusionsThe present results show that the PPV performance of noninvasive prenatal testing for fetal trisomies 13, 18 and 21 are closely associated with Z‐score. The higher the Z‐score, the greater the likelihood that the aneuploidy result is correct. Our experience in evaluating the Z‐score accuracy of NIPT in this study could be of use in similar work.This article is protected by copyright. All rights reserved.

Maternal Prenatal Screening Programs That Predict Trisomy 21, Trisomy 18, and Neural Tube Defects in Offspring

Predictive Significance of Risk Value in Prenatal Screening for Fetal Trisomy 18

Clinical application of noninvasive prenatal testing for the detection of trisomies 21, 18, and 13: a hospital experience.

Noninvasive Prenatal Testing of Trisomies 21 and 18 by Massively Parallel Sequencing of Maternal Plasma DNA in Twin Pregnancies.

Clinical Efficiency of Non-invasive Prenatal Screening for Common Trisomies in Low-Risk and Twin Pregnancies

Efficiency of Non-invasive Prenatal Screening in Pregnant Women at Advanced Maternal Age

Detection of trisomies 13, 18 and 21 using non-invasive prenatal testing

Improved contingent screening strategy increased trisomy 21 detection rate in the second trimester

Discordant performances of non-invasive prenatal testing for foetal trisomy 21 screening in subgroups of pregnancies

[Noninvasive Prenatal Screening for Twin Pregnancy: an Analysis of 2057 Cases].

Non-invasive prenatal testing for the detection of trisomy 13, 18, and 21 and sex chromosome aneuploidies in 68,763 cases

Analysis of Prenatal Serological Screening of 116 Pregnant Women with Trisomy 21 Syndrome Fetus

[First-trimester screening for trisomies 18 and 13 with the combined use of the risk algorithms for trisomy 21, 18 and 13]

[Analysis of the results of chromosomal trisomies 21, 18 and 13 screening among 40 628 women by non-invasive prenatal testing]

Detection of Cell-Free Fetal DNA in Maternal Plasma for Noninvasive Prenatal Screening of Fetal Chromosomal Aneuploidies in Women of Advanced Maternal Age

Diagnostic value of maternal alpha-fetoprotein variants in second-trimester biochemical screening for trisomy 21 and 18

[Prenatal diagnosis and outcome of pregnancy for women with high risks by screening of fetal free DNA from peripheral blood samples]

External Quality Assessment of Maternal Serum Levels of Alpha-Fetoprotein, Free Beta-Human Chorionic Gonadotropin, and Unconjugated Estriol in Detecting Down Syndrome and Neural Tube Defects in the Second Trimester of 87 Maternal Serum Samples, Based on 105-139 Days

[Predictive value of abnormal second-trimester maternal serum triple screening markers for adverse pregnancy outcomes]

Evaluation of the Z‐score accuracy of noninvasive prenatal testing for fetal trisomies 13, 18 and 21 at a single center

Performance evaluation of noninvasive prenatal testing on 24 chromosomes in a cohort of 118,969 pregnant women in Sichuan, China